LONDON - Hemogenyx Pharmaceuticals plc (LSE: HEMO) has announced the successful reclassification and consolidation of its shares following the resolutions passed at its Extraordinary General Meeting on December 9, 2024. The biopharmaceutical company, which specializes in developing treatments for blood diseases, reported that the existing ordinary shares have undergone a subdivision and reclassification process, resulting in the creation of new ordinary shares and deferred shares.
The reclassification involved subdividing each existing ordinary share into one new ordinary share with a nominal value of £0.000025 and one deferred share with a nominal value of £0.009975. This was followed by a consolidation phase where every 400 new ordinary shares were consolidated into one new ordinary share with a value of £0.01 each. As a result, Hemogenyx Pharmaceuticals now has 3,504,539 new ordinary shares in issue.
The new ordinary shares are expected to be admitted to the transition category of the Official List of the Financial Conduct Authority (FCA) and to begin trading on the Main Market of the London Stock Exchange (LON:LSEG) on December 13, 2024. Accompanying this change, the International Securities Identification Number (ISIN) for the new ordinary shares will be updated from GB00BYX3WZ24 to GB00BQVXM815.
The deferred shares will not carry voting rights or the right to participate in the capital of the company, except as specified in the company's Articles of Association, and will not be admitted to trading on any exchange. No certificates will be issued for the deferred shares, nor will they be credited to CREST accounts.
Shareholders are advised to use the total of 3,504,539 new ordinary shares as the denominator for the calculations required to determine whether they need to disclose their interest in, or any changes to their interest in, the company's share capital as per the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
This restructuring is based on a press release statement from Hemogenyx Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.